Marker Therapeutics Inc. sell nvestor
Start price
20.03.21
/
50%
€25.00
Target price
20.03.22
€10.00
Performance (%)
-28.40%
End price
03.04.21
€17.90
Summary
This prediction ended on 03.04.21 with a price of €17.90. The prediction for Marker Therapeutics Inc. closed with a convincing performance of -28.40%. nvestor has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Marker Therapeutics Inc. | -1.266% | -1.266% | 10.874% | -80.859% |
iShares Core DAX® | -0.372% | 5.236% | 16.908% | 16.016% |
iShares Nasdaq 100 | -1.950% | 1.680% | 19.890% | 31.832% |
iShares Nikkei 225® | -1.690% | 7.286% | 12.202% | 3.400% |
iShares S&P 500 | -0.399% | 2.379% | 20.975% | 36.224% |
According to nvestor what are the pros and cons of Marker Therapeutics Inc. for the foreseeable future?
Pros
Higher EBIT margin than peer group
Revenue growth >5% per year expected
Fair valuation
positive Cash Flow expected
Good rating
Valuable balance sheet
Capable Management
Innovative
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
High dividend yield expected
Standard Investments for future growth
ROE higher than 10% per year
Good culture
Small cyclical dependencies
Known brand
Normal challenges to pay loans and raise capital
Top 10 in its market
Future proof or reliable business model
Cons
Comments by nvestor for this prediction
In the thread Marker Therapeutics Inc diskutieren
Sell mit Kursziel 1,0
In the thread Trading Marker Therapeutics Inc
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by nvestor for Marker Therapeutics Inc.
Marker Therapeutics Inc.
Start price
Target price
Perf. (%)
€3.28
09.06.24
09.06.24
€1.00
09.06.25
09.06.25
18.29%
22.06.24
22.06.24
Higher EBIT margin than peer group
Revenue growth >5% per year expected
Fair valuation
positive Cash Flow expected